SWM
BHVN

SeaCrest Wealth Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

SeaCrest Wealth Management’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,825
Closed -$266K – 1642
2022
Q2 		$266K Sell
1,825
-975
-35% -$125K 0.03% 508
2022
Q1 		$332K Sell
2,800
-50
-2% -$6.24K 0.04% 481
2021
Q4 		$393K Buy
2,850
+175
+7% +$22.3K 0.04% 428
2021
Q3 		$372K Buy
2,675
+300
+13% +$37.5K 0.04% 431
2021
Q2 		$231K Buy
+2,375
New +$193K 0.03% 593
2021
Q1 		– Sell
-2,650
Closed -$227K – 696
2020
Q4 		$227K Buy
+2,650
New +$225K 0.03% 527
2019
Q2 		– Sell
-2,165
Closed -$111K – 2222
2019
Q1 		$111K Buy
2,165
+15
+0.7% +$648 0.02% 655
2018
Q4 		$80K Hold
2,150
– – 0.02% 742
2018
Q3 		$81K Sell
2,150
-200
-9% -$7.36K 0.01% 824
2018
Q2 		$93K Buy
2,350
+350
+18% +$11.1K 0.02% 746
2018
Q1 		$52K Sell
2,000
-350
-15% -$10.5K 0.01% 944
2017
Q4 		$63K Buy
+2,350
New +$64.7K 0.01% 877

Other funds holding BHVN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SFM
Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

SeaCrest Wealth Management's BHVN Position: Q3 2022 in Review

SeaCrest Wealth Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2022, closing a stake of 1,825 shares — an estimated $266K sold.

SeaCrest Wealth Management first reported a position in BHVN in Q4 2017 and held it in 12 quarters. The position peaked at $393K in Q4 2021. 240 funds tracked by Wall St. Rank hold BHVN as of Q3 2022.

  • SeaCrest Wealth Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2022 after selling out during the quarter.
  • SeaCrest Wealth Management sold 1,825 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2022, an estimated $266K.
  • SeaCrest Wealth Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2017 and held it in 12 quarters.
  • SeaCrest Wealth Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $393K in Q4 2021.
  • 240 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2022.

Based on SeaCrest Wealth Management's 13F filing for Q3 2022, filed 15 Nov 2022.